Latest in NSCLC from WCLC 2020

Bookmark and Share
Published: 24 Feb 2021
Views: 1202
Prof Solange Peters, Dr Melissa Johnson, Prof Heather Wakelee and Dr Jay Lee

Prof Solange Peters (Lausanne University Hospital, Lausanne, Switzerland), Dr Melissa Johnson (Sarah Cannon Cancer Institute, Tennessee, USA), Prof Heather Wakelee ( Stanford university, California, USA) and Dr Jay M Lee ( UCLA Santa Monica Medical Center, California, USA) discuss the latest in NSCLC from WCLC 2020.

Initially, they discuss the treatment and management of patients with NSCLC and the important types of NSCLC, their diagnostic features and testing.

They then move on to discuss the new treatment paradigms, novel drugs and verified treatment regimens and advances announced at the meeting for patients with NSCLC.

Dr Johnson and Wakelee discuss the IMpower110: updated OS analysis of atezolizumab vs platinum-based chemotherapy as first-Line treatment in PD-L1–selected NSCLC.

Dr Lee talks about the surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC.

Prof Peters also discusses the clinical/biomarker data for neoadjuvant atezolizumab in resectable Stage IB-IIIB NSCLC with the panel.

They further talk about data from other note worthy studies as well like Codebreak 100, KEYNOTE-799, EXCLAIM and ADAURA trial.

This programme has been supported by an unrestricted educational grant from Roche.